GlassScriptPhysician profile
Evelyn S Felluca
NPI 1265506505
$4,390.50
in general payments reported to CMS, 2019-2025
26 companies · $24.17 in 2025
The $24.17 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,248 · 2020: $209 · 2021: $333 · 2022: $476 · 2023: $419 · 2024: $680 · 2025: $24.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.37 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,215.16 | 2019-2024 | Da Vinci Surgical System |
| Astellas Pharma US INC | $346.42 | 2023-2025 | Veozah |
| Abbvie INC. | $338.76 | 2019-2023 | |
| Therapeuticsmd, INC. | $182.33 | 2019-2022 | |
| Axonics, INC. | $158.94 | 2024 | Bulkamid |
| Organon LLC | $125.28 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $113.60 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.06 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $100.82 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $99.67 | 2022 | |
| Baxter Healthcare | $99.56 | 2023 | Tisseel |
| Avion Pharmaceuticals | $93.28 | 2019-2022 | |
| Pfizer INC. | $74.28 | 2021-2023 | |
| Aspira Women'S Health INC | $51.49 | 2022 | |
| Hologic Sales and Service, LLC | $43.25 | 2021-2024 | Aptima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $41.16 | 2022-2023 | Slynd |
| Evofem Biosciences, INC. | $31.58 | 2021-2022 | |
| Lupin INC. | $27.00 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $26.03 | 2019-2020 | |
| Agile Therapeutics, INC. | $18.95 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $18.81 | 2023 | Vivjoa |
| Novo Nordisk INC | $17.20 | 2020 | |
| Allergan, INC. | $16.88 | 2019 | |
| Scynexis, INC. | $15.50 | 2022 | |
| Merck Sharp & Dohme LLC | $14.64 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Felluca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.